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Abstract
Background: Earlier age at menopause has been associated with increased risk of
coronary heart disease (CHD), but the shape of association and role of established car-
diovascular risk factors remain unclear. Therefore, we examined the associations
between menopausal characteristics and CHD risk; the shape of the association between
age at menopause and CHD risk; and the extent to which these associations are
explained by established cardiovascular risk factors.
Methods: We used data from EPIC-CVD, a case–cohort study, which includes data from
23 centres from 10 European countries. We included only women, of whom 10 880 com-
prise the randomly selected sub-cohort, supplemented with 4522 cases outside the sub-
cohort. We conducted Prentice-weighted Cox proportional hazards regressions with age
as the underlying time scale, stratified by country and adjusted for relevant confounders.
Results: After confounder and intermediate adjustment, post-menopausal women were
not at higher CHD risk compared with pre-menopausal women. Among post-
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menopausal women, earlier menopause was linearly associated with higher CHD risk
[HRconfounder and intermediate adjusted per-year decrease¼ 1.02, 95% confidence interval
(CI)¼1.01–1.03, p¼ 0.001]. Women with a surgical menopause were at higher risk of
CHD compared with those with natural menopause (HRconfounder-adjusted¼ 1.25, 95%
CI¼1.10–1.42, p< 0.001), but this attenuated after additional adjustment for age at meno-
pause and intermediates (HR¼ 1.12, 95% CI¼ 0.96–1.29, p¼ 0.15). A proportion of the as-
sociation was explained by cardiovascular risk factors.
Conclusions: Earlier and surgical menopause were associated with higher CHD risk.
These associations could partially be explained by differences in conventional cardiovas-
cular risk factors. These women might benefit from close monitoring of cardiovascular
risk factors and disease.
Key words: Menopause, coronary disease, ageing, Epidemiology, women, risk factors
Introduction
Cardiovascular disease (CVD) is the leading cause of death
in men and women from Western countries, with
17.5 million deaths worldwide in 2012, representing 31%
of all global deaths.1 Approximately 7.4 million of these
were due to coronary heart disease (CHD). CHD risk
increases in women after the age of 50 years, leading to sug-
gestions that menopause may be a contributing factor.2–4 A
recent meta-analysis suggested that women who had early
menopause (before age 45 years) are at 50% higher CHD
risk compared with those with later menopause.5 However,
that analysis was not able to include 9 studies out of the 14
studies they found examining the association between age
at menopause and CHD, nor was it able to examine
whether there is a (non-)linear dose–response relationship
or threshold effect or whether type of menopause (surgical
or natural) was associated with CHD risk.
The biological mechanisms through which menopause
might influence CHD risk are postulated to include reductions
in oestrogen levels, but rises in conventional cardiovascular
risk factors (e.g. major lipids and blood pressure) around the
time of menopause may also play a role.6–8 However, the
extent to which the association between menopausal
characteristics and CHD can be explained by such factors
remains unclear.
We conducted a large pan-European prospective case–
cohort study (EPIC-CVD) with an average of 11 years of
follow-up to quantify the associations of menopausal status,
age at menopause and type of menopause with risk of CHD;
we also examined the shape of the relationship between age
at menopause (as a continuous exposure) and risk of CHD;
and we assessed the extent to which the associations of men-
opausal characteristics with risk of CHD could be explained
by established cardiovascular risk factors.
Methods
Participants
We used data from female participants in the EPIC-CVD
study—a case–cohort study nested within the European
Prospective Investigation into Cancer and Nutrition (EPIC)
study.9 EPIC consists of 519 978 adults (366 521 women),
aged between 35 and 70 years at baseline, and recruited from
23 centres across 10 European countries (Denmark, France,
Germany, Greece, Italy, The Netherlands, Norway, Spain,
Sweden and the UK) between 1992 and 2000. Baseline ques-
tionnaires included questions on diet, lifestyle, reproductive
and medical factors. Blood samples were collected for ap-
proximately 70% of the participants and stored in liquid
nitrogen at –196C. For EPIC-CVD, a representative
Key Messages
• Age at menopause has an inverse dose–response relationship with coronary heart disease (CHD) risk.
• Surgical menopause is associated with an increased CHD risk, even after accounting for age at menopause.
• A proportion of the risk appears to be explained by cardiovascular risk factors.
• As a residual association between menopausal characteristics and CHD remains and the mechanism is not fully un-
derstood, this merits further research.
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sub-cohort of 18 249 participants was selected by simple ran-
dom sampling, stratified by centre, from participants who
had available stored blood and buffy coat samples.10,11 After
exclusion of 609 participants with a prior history of myocar-
dial infarction or stroke at baseline, 17 640 sub-cohort mem-
bers remained. After subsequent exclusion of the 6760 men,
a sub-cohort of 10 880 women remained, of whom 231 had
a CHD event. Subsequently, incident CHD cases in women
outside the sub-cohort were added to the study sample using
the same exclusion criteria (N¼4522).
EPIC complies with the Declaration of Helsinki, and all
participants gave written informed consent before partici-
pating in this study. The study was approved by the local
ethics committees of the participating centres and the
Institutional Review Board of the International Agency for
Research on Cancer (IARC, Lyon).
Menopausal status, timing and type of
menopause
Menopause was assessed by questionnaire at baseline.
Women were categorized as pre-menopausal if they had ex-
perienced menses over the past 12 months before recruitment
and by design, for women with missing or incomplete ques-
tionnaires, if they were 54 years or younger at recruitment.
The pre-menopausal group also includes the peri-menopausal
women, since numbers were too small to analyse them as a
separate group. Women were categorized as post-meno-
pausal if they had experienced no menses for 12 months or
longer due to natural or surgical menopause and by design,
for women with missing or incomplete questionnaire data, if
they were 55 years or older at recruitment.12
Post-menopausal women were classified as having had a
natural or surgical menopause, where surgical menopause
was defined as having had a hysterectomy, unilateral or bi-
lateral oophorectomy, only when age at surgery preceded
or was equal to age at menopause. In the Malmö centre,
since the age at removal of a woman’s womb and/or one or
both ovaries was not recorded, women were classified as
having had a surgical menopause regardless of age at sur-
gery and age at menopause was then imputed (see below).
For naturally post-menopausal women, age at menopause
was defined as the age at which they had their last menstru-
ation. For surgically post-menopausal women, their age at
surgery was used instead. Since most other studies compare
early menopause with late menopause, we present risk asso-
ciations for decreases (rather than increases) in age at men-
opause, by multiplying age at menopause by –1.
Covariate measurement
Baseline questionnaires included questions on age, smok-
ing status (current, former, never), highest education level
(no schooling/primary school, secondary school, voca-
tional education/university), age at menarche (10, 11, 12,
13, 14, 15, 16, 17 years), full-term pregnancy (yes/no)
and whether participants had ever used post-menopausal
hormones (yes/no). All centres used trained professionals
to measure height and weight except the French centre, for
which self-reported measures were used for a subset of par-
ticipants, and Oxford, for which recalibrated self-reported
measures were used based on a comparison between self-
reported and measured data in a subset of participants.
Both height and weight were adjusted for clothing
worn.9,13 Body mass index (BMI) was calculated as weight
divided by the square of height in metres and was categor-
ized (20, >20 to <25, 25 to <30, 30 kg/m2). Physical
activity was categorized using the Cambridge Physical
Activity Index into inactive, moderately inactive, moder-
ately active and active.14 Baseline systolic and diastolic
blood pressure measurements were available in 62% of
participants.11 Therefore, to maximize the availability of
information, we used a composite variable (‘high blood
pressure’, available in 98% of participants) defined as any
of self-reported hypertension, self-reported use of anti-
hypertensive medication, systolic blood pressure
>140 mmHg or diastolic blood pressure >90 mmHg.
Serum biomarkers were measured in baseline non-
fasted samples at Stichting Huisartsen Laboratorium
(Etten-Leur, The Netherlands) and included high-
sensitivity C-reactive protein (hsCRP), total cholesterol,
high-density lipoprotein cholesterol (HDL-c) and triglycer-
ides. Erythrocyte haemoglobin A1c (HbA1c) was measured
using the Tosoh-G8 HPLC analyser (Tosoh Bioscience,
Japan); all other biomarkers were measured using a Cobas
enzymatic assay (Roche Diagnostics, Mannheim,
Germany) on a Roche HitachiModular P analyser.
First fatal or non-fatal CHD event
First fatal or non-fatal CHD events were defined by codes
410–414 of the International classification of diseases Ninth
Edition (ICD-9) and codes I20–I25 of the Tenth Edition
(ICD-10). Methods used in the recruitment centres to deter-
mine first non-fatal CHD events included self-report and
linkage with morbidity or hospital registries. Non-fatal CHD
events were further validated by a review of medical records
and/or linkage with registries. Fatal CHD events were gener-
ally determined through mortality registries.11 The final year
of follow-up for CHD events varied between centres from
2003 to 2010 and median follow-up time was 11 years.
Statistical analyses
Missing values in the exposures and covariates were im-
puted with multiple imputation using the package MICE in







niversity Library of Trom
sø user on 09 January 2020
R15 with 10 imputations and 50 iterations (Supplementary
Appendix 1, available as Supplementary data at IJE on-
line). Women from Norway were excluded prior to impu-
tation due to high levels of missing data. Hazard ratios
were estimated using Prentice-weighted Cox proportional
hazards regression, with age as the underlying time scale
and with country-stratified baseline hazards.16 Robust
standard errors were used to construct 95% confidence
intervals (CIs). In order to study the association between
menopausal characteristics and CHD, three levels of covar-
iate adjustment were applied: adjustment for age at base-
line only (age-adjusted model), further adjustment for
CHD and reproductive risk factors: smoking status, BMI,
HbA1c, education level, physical activity, age at menarche,
full-term pregnancy and ever hormone use (confounder-ad-
justed model). The third model—the confounder- and in-
termediate-adjusted model—additionally includes the
established cardiovascular risk factors that might mediate
the association between menopausal characteristics and
CHD (total cholesterol, HDL-c, triglycerides, high blood
pressure and C-reactive protein). Since the association be-
tween menopausal age and CHD may vary depending on
smoking and obesity status,17 we also assessed effect-
modification by including interaction terms between men-
opausal age and smoking status and between menopausal
age and obesity status, respectively, in the confounder-
adjusted model. Surgically post-menopausal women tend
to have an earlier age at menopause.18–20 Thus, the analy-
sis of type of menopause was also adjusted for age at men-
opause (Model 3b).
To verify the expected linear relationship between age
at menopause and CHD, we used floating absolute risks to
display the hazard ratios (HRs) for age at menopause cate-
gories [<40, 40–44, 45–49, 50–54, >55 years (reference)]
and CHD risk in the confounder-adjusted model. Instead
of using a fixed value for the reference group, floating ab-
solute risks redistribute the overall variance across the
groups, which results in a reference category with a CI and
narrower CIs for the other categories.21
To estimate the proportion of the association between
menopause and CHD risk that could be explained by po-
tential mediators that were also CVD risk factors, we used
the difference method22,23 for which two regression coeffi-
cients of the exposure–outcome association are required:
the direct effect (i.e. with adjustment for the possible medi-
ators or established CVD risk factors) and the total effect
(without adjustment). First, the total effect of each meno-
pausal characteristic on CHD was estimated based on
Model 1 (adjusted for age). Subsequently, for each model
of adjustment separately, we estimated the direct effect
when removing the indirect via the added risk factors. The
proportion of the effect explained (PE) by the mediators
was then calculated as: PE¼ (total effect – direct effect)/to-
tal effect, where effects were considered on the logarithmic
scale, i.e. log(HR). Thereafter, we performed the same
analyses for each separate risk factor. Bootstrap re-sam-
pling (1000 bootstrap samples) was used to obtain 95%
CIs around the PE (Supplementary Appendix 1, available
as Supplementary data at IJE online).
We performed three sensitivity analyses: (i) restricting to
women who had never used hormone therapy, since age at
menopause may be difficult to determine under hormone
use and the effects of surgical menopause on CHD are atten-
uated in women using hormone therapy (HT)24–26;
(ii) excluding the first 2 years of follow-up to reduce the like-
lihood of reverse causality; (iii) excluding women with uni-
lateral oophorectomy or hysterectomy from the surgical
menopause category to reflect alternative definitions of sur-
gical menopause used previously. We also conducted a com-
plete case analysis and compared results with the multiple
imputation approach. All analyses were performed on each
imputed dataset separately and the estimates were pooled
using Rubin’s rules,27 with R version 3.2.0.28
Results
After exclusions, there were 10 880 women in the sub-co-
hort and 4753 incident CHD cases (231 of whom were
also in the sub-cohort) comprising a total of 15 402 partici-
pants, of whom 5486 were pre-menopausal and 9916 were
post-menopausal. Compared with pre-menopausal
women, post-menopausal women in the sub-cohort were
older, less likely to be smokers, less educated, more likely
to have a history of high blood pressure and had higher to-
tal cholesterol levels and BMI (Table 1). Mean age at men-
opause was 49.2 years [standard deviation (SD) 4.5] for
women with a natural menopause and 45.1 years (SD 5.8)
for women with a surgical menopause. Within post-meno-
pausal women, natural post-menopausal women more of-
ten had a high blood pressure, less often used HT and they
had a higher age at menopause compared with surgical
post-menopausal women (Supplementary Appendix Table
1, available as Supplementary data at IJE online).
Post-menopausal women had a higher CHD risk com-
pared with pre-menopausal women (age-adjusted model
HR¼ 1.23, 95% CI: 1.08–1.40, p-value¼ 0.002)
(Table 2), but this attenuated in the confounder- and inter-
mediate-adjusted model (HR¼ 1.08, 95% CI: 0.93–1.26,
p-value¼ 0.29).
Age at menopause had an approximately linear associa-
tion with CHD risk, with women in the lowest category
(menopausal age <40 years) having a 51% (confounder-
adjusted model HR¼ 1.51, 95% CI: 1.15–1.98),
p¼ 0.003) higher risk than those in the highest category
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(menopausal age 55 years) (Figure 1). In addition, Table 3
showed that, for each 1-year decrease in age at menopause,
CHD risk was 2% higher (HRconfounder and intermediate adjusted
¼ 1.02, 95% CI: 1.01–1.03, p< 0.001) and, for each SD
decrease (7.9 years) in age at menopause, risk was 14%
higher (HRconfounder and intermediate adjusted¼ 1.14, 95% CI:
1.05–1.22, p¼ 0.001).
Post-menopausal women with a surgical menopause
had a higher risk of CHD compared with women with a
natural menopause (HRconfounder-adjusted¼ 1.25, 95% CI:
Table 1. Baseline characteristics of women in the sub-cohort of the EPIC-CVD case–cohort study
Pre-menopausal (N¼5486) Post-menopausal (N¼9916)
CHD risk factors
Age at baseline (years) 44.8 6 6.5 59.7 6 6.8
Smoking status
Never 2788 (51.7%) 5386 (55.0%)
Former 1133 (21.0%) 2141 (21.9%)
Current 1474 (27.3%) 2266 (23.1%)
Body mass index (kg/m2)a
20 390 (7.2%) 418 (4.2%)
>20 to <25 2543 (46.7%) 3653 (37.0%)
25 to <30 1679 (30.9%) 3739 (37.9%)
30 828 (15.2%) 2057 (20.8%)
Physical activity
Inactive 1448 (26.8%) 3155 (32.2%)
Moderately inactive 1871 (34.6%) 3313 (33.9%)
Moderately active 1188 (22.0%) 1798 (18.4%)
Active 894 (16.6%) 1517 (15.5%)
Education level
No schooling/primary school 1926 (35.9%) 4926 (52.0%)
Secondary school 1065 (19.8%) 1174 (12.4%)
Vocational/university 2376 (44.3%) 3380 (35.7%)
High blood pressure (history) 1249 (23.0%) 5201 (53.4%)
HbA1c (%)b 5.4 (5.1-5.5) 5.6 (5.4-5.8)
hsCRP (mg/L)b 1.0 (0.4-2.2) 1.5 (0.7-3.3)
Total cholesterol (mmol/L) 5.6 6 1.0 6.4 6 1.2
HDL cholesterol (mmol/L) 1.6 6 0.4 1.5 6 0.4
Triglycerides (mmol/L)b 0.9 (0.7-1.3) 1.2 (0.9-1.8)
Reproductive factors
Age at menopause (years)c – 47.6 6 5.6
Full-term pregnancy (Yes) 4415 (87.0%) 8562 (88.5%)
Ever hormone use (Yes) 444 (9.4%) 3006 (33.8%)
Age at menarche (years)
10 209 (4.1%) 271 (2.8%)
11 698 (13.6%) 1006 (10.4%)
12 1270 (24.7%) 1733 (18.0%)
13 1330 (25.8%) 2228 (23.1%)
14 1051 (20.4%) 2235 (23.2%)
15 375 (7.3%) 1208 (12.5%)
16 156 (3.0%) 595 (6.2%)
17 57 (1.1%) 365 (3.8%)
Follow-up
Number of events 679 (12.4%) 4074 (41.1%)
Age at event 56.4 6 7.1 69.8 6 7.0
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1.10–1.42, p< 0.001), which attenuated on further adjust-
ment for age at menopause (HRconfounder-adjusted(b)¼ 1.15,
95% CI: 1.00–1.33, p¼ 0.05) and intermediates
(HRconfounder and intermediate adjusted¼ 1.12, 95% CI: 0.96–
1.29, p¼ 0.15) (Table 4).
In the association between age at menopause and CHD,
BMI was an effect modifier (p¼ 0.003) where smoking was
not (p¼ 0.56). The BMI stratified results (Supplementary
Appendix Table 2, available as Supplementary data at IJE
online) showed that, in women with a BMI of 25 or higher,
each 1-year decrease in age at menopause resulted in a 2 or
4% higher CHD risk (HRconfounder and intermediate adjusted
[BMI25–<30] 1.02, 95% CI: 1.01–1.04, p-value¼ 0.01;
HRconfounder and intermediate adjusted[BMI 30] 1.04, 95%
CI: 1.02–1.06, p-value< 0.001). Women with a BMI
between >20 and <25 had no increased CHD risk
(HRconfounder and intermediate adjusted¼ 1.00, 95% CI: 0.99–
1.02, p¼ 0.66) and women with a BMI 20 had a 1%
increase in CHD risk for each 1-year decrease in age at
menopause (HRconfounder and intermediate adjusted¼ 1.01, 95%
CI: 0.97–1.07, p-value¼ 0.56).
Finally, in all analyses, we added possible mediators for
the associations in Model 4. For post-menopausal compared
with pre-menopausal women, we found that adding the
Table 2. Hazard ratio (HR) and 95% confidence intervals (CIs) for the association between menopausal status and any first CHD
event
Post-menopausal vs pre-menopausal
Model HR (95% CI) p-value PE% (95% CI)a
Age-adjusted model 1.23 (1.08–1.40) 0.002 /
Confounder-adjusted modelb 1.13 (0.98–1.30) 0.09 40.5 (30.4–54.6)
Confounder- and intermediate-adjusted modelc 1.08 (0.93–1.26) 0.29 60.7 (54.4–80.6)
N (N of events): post-menopausal 9916 (4074), pre-menopausal 5486 (679).
aPE, proportion explained.
bAdjusted for baseline age, smoking status, BMI, HbA1c, education level, physical activity, full-term pregnancy, age at menarche and ever hormone use.
cAdditionally adjusted for high-sensitivity C-reactive protein, total cholesterol, HDL-cholesterol, triglycerides and high blood pressure.
Figure 1. Graphical display of the linear relationship between age at menopause and CHD using floating absolute risks to display the hazard ratios
(HRs) for age at menopause categories [<40, 40–44, 45–49, 50–54, 55 years (reference), with 364, 551, 1284, 1563, 312 CHD events, respectively].
HRs were plotted against the mean age at menopause of each category, which are 34, 42, 47, 51 and 57 accordingly.
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established risk factors in Model 4 explains an additional
20% of the association compared with the confounder-
adjusted Model 3 (Table 2). In the association with age at
menopause, the possible mediators or established risk fac-
tors explained an additional 10% of the association com-
pared with the confounder-adjusted model, although the
HR only slightly changes (Table 4). Finally, for types of
menopause, the possible mediators explained an additional
part of the association of approximately 10% compared
with model confounder and age at menopause adjusted
model. However, in this case, it seemed that age at meno-
pause explained the largest part of the association (Table 3).
Furthermore, Supplementary Appendix Table 3, available
as Supplementary data at IJE online, shows the proportion
explained of all the risk factors separately.
Sensitivity analyses
Similar results were obtained in analyses that were re-
stricted to women who never used HT (Supplementary
Appendix Tables 4–6, available as Supplementary data at
IJE online) and that excluded the first 2 years of follow-up
(Supplementary Appendix Tables 7–9, available as
Supplementary data at IJE online). When surgical meno-
pause was defined as bilateral oophorectomy only, the risk
estimates for menopausal status attenuated compared with
the main analyses (HRconfounder and intermediate adjusted¼0.95,
95% CI: 0.82–1.10, p¼0.50) as did the results for type of
menopause (HRconfounder and intermediate adjusted¼ 0.92, 95%
CI¼ 0.74–1.15, p¼0.47) (Supplementary Appendix Tables
10 and 11, available as Supplementary data at IJE online).
The complete case analysis (data not shown) gave similar
results to those from the multiple imputation approach.
Discussion
Our study has shown that age at menopause has an inverse
dose–response relationship with risk of CHD. Surgical
menopause is also associated with an increased CHD risk,
even once the earlier age at menopause is accounted for. A
proportion of the risk appears to be explained by cardio-
vascular risk factors that have been postulated to mediate
the associations of menopausal characteristics with risk of
CHD.
Table 3. Hazard ratio (HR) and 95% confidence intervals (CIs) for the association between age at menopause and any first CHD
event in post-menopausal women
HR per-year decrease in age at menopause HR per SD decrease in age at menopause
Model HR (95% CI) p-value HR (95% CI) p-value PE% (95% CI)a
Age-adjusted model 1.03 (1.02–1.04) <0.001 1.23 (1.15–1.33) <0.001 –
Confounder-adjusted modelb 1.02 (1.01–1.03) <0.001 1.16 (1.08–1.25) <0.001 28.6 (23.2–34.5)
Confounder- and intermediate-
adjusted modelc
1.02 (1.01–1.03) <0.001 1.14 (1.05–1.23) <0.001 38.7 (30.4–44.6)
N (N of events): 9916 (4074).
aPE, proportion explained.
bAdjusted for baseline age, smoking status, BMI, HbA1c, education level, physical activity, full-term pregnancy, age at menarche and ever hormone use.
cAdditionally adjusted for high-sensitivity C-reactive protein, total cholesterol, HDL-cholesterol, triglycerides and high blood pressure.
Table 4. Hazard ratio (HR) and 95% confidence intervals (CIs) for the association between type of menopause and any first CHD
event in post-menopausal women
Surgical vs natural menopause
Model HR (95% CI) p-value PE% (95% CI)a
Age-adjusted model 1.31 (1.16–1.47) <0.001 /
Confounder-adjusted modelb 1.25 (1.10–1.42) <0.001 17.6 (10.4–25.4)
Confounder-adjusted model(b)c 1.15 (1.00–1.33) 0.05 47.2 (37.3–59.1)
Confounder- and intermediate-adjusted modeld 1.12 (0.96–1.29) 0.15 59.2 (46.6–73.5)
N (N of events): surgical 2206 (935), natural 7710 (3139).
aPE, proportion explained.
bAdjusted for baseline age, smoking status, BMI, HbA1c, education level, physical activity, full-term pregnancy, age at menarche and ever hormone use.
cAdditionally adjusted for age at menopause.
dAdditionally adjusted for high-sensitivity C-reactive protein, total cholesterol, HDL-cholesterol, triglycerides and high blood pressure.
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Our finding that the higher risk of CHD in post-meno-
pausal women attenuated upon adjustment for conven-
tional cardiovascular risk factors and reproductive factors
is in line with a previous meta-analysis29 that also found an
increased risk for post-menopausal women. These analyses
could be challenging, since one might expect both pre- and
post-menopausal women to have their events around the
same age in their post-menopausal period. However, the
age at event in our study was 56.4 6 7.1 years for pre-men-
opausal women and 69.8 6 7.0 years for post-menopausal
women, indicating enough dispersion to show a robust ef-
fect. Similarly, our finding that earlier menopause is associ-
ated with a higher CHD risk is also consistent with a recent
meta-analysis5 that showed a higher CHD risk for women
with an age at menopause before 45 years. However, our
access to individual participant data (rather than literature-
based summary results) meant that we were able to amplify
previous findings by showing that the relationship is contin-
uous and approximately linear across the range in age at
menopause. Hence, there is no clear age threshold below
which early menopause appears to be of intrinsic concern,
within the approximate mean ages of the earliest (34 years)
and latest (56 years) categories of menopausal age. Age at
menopause might be harder to recall when women used
HT, but the results of the sensitivity analysis excluding
women using HT barely changed, indicating that this did
not influence our results. We identified BMI as an effect
modifier and the stratified results appeared similar to the
findings of a smaller study,18 which suggested that age at
menopause has a stronger association with CHD in obese
women compared with non-obese women.
Previous evidence on the associations of surgical and
natural menopause with CHD is conflicting.2,3,24,30,31
Comparison of these studies is difficult, since the definition
of surgical menopause and inclusion of women using HT
differs by study. Notably, none of the studies on surgical
menopause adjusted for age at menopause in their analysis,
notwithstanding the fact that a surgical menopause occurs
consistently earlier than a natural menopause. Our study
shows that the association between surgical menopause
and CHD risk is largely explained by the earlier age at
menopause, but residual risk remains. Excluding women
using HT only slightly altered the results. However, when
we defined surgical menopause as bilateral oophorectomy
only, the results attenuated towards the null, suggesting
that the effect of surgical menopause might be smaller than
previously thought.
As conventional cardiovascular risk factors such as
blood pressure, lipids and C-reactive protein (CRP) rise
around the age of menopause, we specifically examined
the extent to which these potential mediators explained the
associations we observed in Model 4. Our analyses sug-
gested that these factors can explain part of the association
between menopausal characteristics and higher risk of
CHD, because the greatest difference in the percentage of
proportion explained was found between Model 3 and
Model 4 in each association. This concurs with the findings
of several other studies, which showed the greatest changes
in lipid levels around the time of menopausal transi-
tion.7,8,32–36 Our results should be interpreted with cau-
tion, as measurement error might exist in the mediators
that could distort the adjustment.37 Furthermore, as EPIC-
CVD has only a single measure of these risk factors at
baseline (i.e. after the menopause in post-menopausal
women), it is not possible to reliably distinguish whether
the attenuations seen are due to mediation or
confounding.38
Our study has several strengths. We used data from a
large prospective study encompassing diverse European
populations with a long duration of follow-up and a sub-
stantial number of validated incident CHD events. The
availability of a wide range of cardiovascular and repro-
ductive risk factors allowed us to systematically examine
the effects of accounting for these factors. We were also
able to examine the impact of HT use, which has not been
possible in many previous studies. Potential limitations in-
clude missing or incomplete menopause data, which may
have led to non-differential misclassification resulting in
under-estimation of the true associations39; self-reported
menopausal characteristics, although studies show that the
validity is rather good for menopausal status and age and
varies for surgical menopause40–42; the possibility of resid-
ual confounding; and measurement error in the intermedi-
ates. As EPIC-CVD did not have measures of sex
hormones, we were not able to evaluate the contribution
of oestrogen. The fact that there are HT users among pre-
menopausal women can be explained by the inclusion of
peri-menopausal women in this category. Finally, a sub-
stantial number of the pre-menopausal women would
likely have become post-menopausal during the follow-up
period. Therefore, our associations may have been slightly
underestimated.
In conclusion, earlier age at menopause and surgical
menopause are both associated with higher risk of CHD,
which might suggest that these women need close monitor-
ing in clinical practice. The excess risk is, in part, explained
by conventional cardiovascular risk factors. Therefore,
these risk factors should play an important role in the mon-
itoring of these women. However, there is still a residual
association between menopausal characteristics and CHD,
of which the mechanism is not fully understood and which
merits further research.







niversity Library of Trom
sø user on 09 January 2020
Supplementary Data
Supplementary data are available at IJE online.
Funding
This work was supported by the European Union Framework 7
(HEALTH-F2-2012–279233), the European Research Council
(268834), the UK Medical Research Council (G0800270, MR/
L003120/1), the British Heart Foundation (SP/09/002, RG/08/014,
RG13/13/30194) and the UK National Institute of Health Research
(to EPIC-CVD). The national cohorts are supported by the Danish
Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave
Roussy, Mutuelle Générale de l’Education Nationale, Institut
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